Skip to main content

Advertisement

SpringerLink
Log in

Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer

  • Research
  • Published:
Pathology & Oncology Research

Abstract

In a previous study, survivin mRNA expression in non-small cell lung cancer (NSCLC) tissue had been demonstrated to be associated with unfavorable prognosis of patients treated with chemotherapy. In this study, we investigated the survivin mRNA levels in blood of patients with stage IIIA-N2 NSCLC and their association with the efficacy of neoadjuvant chemotherapy (NCT) and disease-free survival (DFS) and overall survival (OS). Blood specimens were collected from 56 patients with stage IIIA-N2 NSCLC before (N0) and after the complete of NCT (N1). Survivin mRNA was measured by real-time quantitative-PCR assay. Receiver operating characteristics curve analysis was undertaken to determine the best cutoff value for survivin mRNA. Results showed that high blood survivin mRNA levels at N0 and N1 were significantly associated with clinical (P = 0.01 and P = 0.008, respectively) and pathologic response (both P = 0.004, respectively). Moreover, the change of blood survivin mRNA levels in these NSCLC patients is associated with the clinical and pathologic response to NCT. Patients with high survivin mRNA levels at N0 and N1 had significantly shorter DFS and OS than those with low survivin mRNA levels (P = 0.021 and P = 0.014, respectively for DFS; P = 0.009 and P = 0.005, respectively for OS). Multivariate analysis demonstrated that high blood survivin mRNA level was an independent predictor for worse DFS and OS in the NSCLC patients receiving NCT. In conclusion, survivin mRNA level in blood from stage IIIA-N2 NSCLC patients receiving NCT is predictive of cancer outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Li J, Dai C-H, Yu L-C et al (2009) Results of trimodality therapy in patients with stage IIIA (N2-Bulky) and stage IIIB non-small cell lung cancer. Clin Lung Cancer 10:353–359

    Article  CAS  PubMed  Google Scholar 

  2. Roth JA, Atkinson EN, Fossella F et al (1998) Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21:1–6

    Article  CAS  PubMed  Google Scholar 

  3. Stefani A, Alifano M, Bobbio A et al (2010) Which patients should be operated after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7 year experience in 175 patients. J Thorac Cardiovase Surg 140:356–363

    Article  Google Scholar 

  4. Rosell R, Gomez-Codina J, Camps C et al (1999) Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized clinical trial. Lung Cancer 26:7–14

    Article  CAS  PubMed  Google Scholar 

  5. Depierre A, Milleron B, Moro-Sibilot D et al (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2:247–253

    Article  Google Scholar 

  6. Song W-A, Zhou N-K, Wang W et al (2010) Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer. An updated meta-analysis of 13 randomized control trials. J Thorac Oncol 5:510–516

    Article  PubMed  Google Scholar 

  7. Detterbeck FC, Boffa DJ, Tanoue LT (2009) The new lung cancer staging system. Chest 36:260–271

    Article  Google Scholar 

  8. Felip E, Stahel RA, Pavlidis N (2005) ESMO minimum clinical recommendation for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Ann Oncol 16:128–129

    Google Scholar 

  9. Ramnath N, Dilling TJ, Harris LJ et al (2013) Treatment of stage IIIA non-small cell lung cancer: diagnosis and management of lung cancer, 3rd: American College of Chest physicians evidence-based clinical practice guidelines. Chest 143(5 suppl):e 314s–e 340s

    Article  CAS  Google Scholar 

  10. Strauss GM (1999) Role of chemotherapy in stage I-III non-small cell lung cancer. Chest 116(6 suppl):509s–516s

    Article  CAS  PubMed  Google Scholar 

  11. Bueno R, Richards WG, Swanson SJ et al (2000) Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 70:1826–1831

    Article  CAS  PubMed  Google Scholar 

  12. Bepler G, Sommers KE, Cantor A et al (2008) Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small-cell lung cancer. J Thorax Oncol 3:1112–1118

    Article  Google Scholar 

  13. John T, Starmans MHW, Chen Y-T et al (2013) The role of cancer-testis antigens as predictive and prognostic markers in non-small cell lung cancer. PLoS ONE 8:e67876

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54

    Article  CAS  PubMed  Google Scholar 

  15. Ambrosini G, Adida C, Alfieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921

    Article  CAS  PubMed  Google Scholar 

  16. Velculescu VE, Madden SL, Zhang L et al (1999) Analysis of human transcriptomes. Nat Genet 23:387–388

    Article  CAS  PubMed  Google Scholar 

  17. Fukud S, Pelus LM (2006) Survivin, a cancer target with an emerging role in normal adult tissue. Mol Cancer Ther 5:1087–1098

    Article  Google Scholar 

  18. Dai C-H, Li J, Shi S-B et al (2010) Survivin and smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 40:327–335

    Article  PubMed  Google Scholar 

  19. Chen P, Li J, Ge L-P et al (2010) Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. Respirology 15:501–509

    Article  PubMed  Google Scholar 

  20. Tang X-P, Li J, Yu L-C et al (2013) Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery. Lung Cancer 8:273–279

    Article  Google Scholar 

  21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guideline to evaluate the response to treatment in solid tumor. European Organization for Research and Treatment for Cancer, National Cancer Institute the United State, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  22. de Bore RH, Snith IE, Pastorino U et al (1999) Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicenter phase III trial. Br J Cancer 79:1514–1518

    Article  Google Scholar 

  23. Livak KJ, Schimittgen TD (2001) Analysis of reactive gene expression data using real-time quantitative PCR and 2-△△Ct method. Method 25:402–408

    Article  CAS  Google Scholar 

  24. Goldstraw P, Crowley J, Chansky K et al (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (Seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol 2:706–714

    Article  PubMed  Google Scholar 

  25. Junker K, Langner K, Klinke F et al (2001) Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest 120:1584–1591

    Article  CAS  PubMed  Google Scholar 

  26. Betticher DC, Schmitz S-FH, Totsch M et al (2003) Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21:1752–1759

    Article  CAS  PubMed  Google Scholar 

  27. Pisters KM, Ginsbery RJ, Giroux DJ et al (2000) Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovase Surg 119:429–439

    Article  CAS  Google Scholar 

  28. Betticher DC, Schmitz S-FH, Totsch M et al (2006) Prognostic factors affecting long-term outcomes in patients with resected stage IIIA non-small-cell lung cancer: 5 year follow-up of a phase II study. Br J Cancer 94:1099–1106

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Singhal S, Vachani A, Antin-Ozerkis D et al (2005) Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11:3974–3986

    Article  CAS  PubMed  Google Scholar 

  30. Crino L, Weder W, van Meerbeeck J et al (2010) On behalf of the ESMO Guidelines Working Group. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(supp1 5):v103–v115

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors have declared that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Street, Zhenjiang, 212001, China

    Yi-Ming Hu, Jing Li, Yong-Jie Du & Wei Lin Shi

  2. Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, Zhengjian, 212001, China

    Li-Chao Yu & Shun-Bing Shi

  3. Department of Pathology, Affiliated Hospital of Jiangsu University, Zhengjian, 212001, China

    Jian-Nong Wu

Authors
  1. Yi-Ming Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li-Chao Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shun-Bing Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong-Jie Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jian-Nong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei Lin Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jing Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hu, YM., Li, J., Yu, LC. et al. Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer. Pathol. Oncol. Res. 21, 257–265 (2015). https://doi.org/10.1007/s12253-014-9816-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-014-9816-4

Keywords

Search

Navigation